ArticleBMC pregnancy and childbirth2026
Integration of single-cell sequencing and transcriptomic analysis to identify novel diagnostic biomarkers for pre-eclampsia.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPre-eclampsia is a significant obstetric complication. Immune cells within the maternal circulatory system hold substantial promises for the diagnosis and treatment of pre-eclampsia. However, research focusing on the maternal circulatory system remains inadequate.
methodsWe conducted differential analysis and weighted correlation network analysis on a dataset to identify blood biomarkers for early-onset pre-eclampsia. These biomarkers were subsequently validated through ELISA. Multiple bioinformatic analyses were subsequently performed to predict the biological functions associated with the selected genes and potential protein‒miRNA regulatory relationships. Additionally, by analysing single-cell transcriptomic data from blood samples, we predicted the genetic profiles of the selected genes, investigated changes in the proportion of blood immune cells and abnormalities in intercellular communication in the pathogenesis of pre-eclampsia, and predicted potential protein-compound interactions.
resultsWe identified and validated the expression levels of F2R-like trypsin receptor 1 (F2RL1) and granzyme H (GZMH) in maternal blood samples obtained from women with and without pre-eclampsia. Gene set enrichment analysis revealed that F2RL1 participates in the regulation of classic signaling pathways, including the Toll-like receptor signaling pathway, pattern recognition receptor signaling pathway, oxidative stress-induced endogenous apoptosis signaling pathway, and vesicle targeting process. GZMH primarily contributes to immune processes associated with natural killer cells. Analysis of single-cell sequencing datasets revealed significant alterations in T cells and haematopoietic stem cell growth factor (HSC-G-CSF) within the maternal blood system during the onset of pre-eclampsia. Furthermore, receptor-ligand interaction analysis and protein-compound interaction analysis highlighted the critical role of aspirin in alleviating pre-eclampsia pathology, while also revealing the potential therapeutic value of tyrosine kinase inhibitors.
conclusionThis study identified the pre-eclampsia biomarkers F2RL1 and GZMH, which showed good diagnostic value. This research provides new insights for the prediction of pre-eclampsia and deepens our understanding of changes in the maternal blood immune system during pre-eclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.